Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management
The once-weekly injectable supports weight loss when used alongside a reduced-calorie diet and increased physical activity.
The launch marks a step toward evidence-based, compassionate treatment of obesity as a chronic disease—not a personal failing.
SINGAPORE – Media OutReach Newswire – 12 July 2025 – A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy® (semaglutide 2.4mg) in Singapore.
Wegovy® (semaglutide 2.4mg) is a once-weekly injectable treatment indicated for chronic weight management in adults and adolescents (aged 12 and above) living with obesity (BMI ≥30 kg/m²), or who are overweight (BMI ≥27 kg/m² to <30 kg/m²) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia1. It is used alongside a reduced-calorie diet and increased physical activity, supporting Singapore's efforts to improve population health.
The treatment works by addressing one of the underlying biological drivers of obesity. Wegovy® (semaglutide 2.4mg) is a GLP-1 receptor agonist with 94% similarity to the body's natural GLP-1 hormone. It activates receptors involved in appetite regulation, helping individuals feel full sooner and reduce food intake1. This mechanism supports weight loss when combined with sustainable lifestyle changes.
ADVERTISEMENT
The availability of Wegovy® (semaglutide 2.4mg) comes as obesity continues to pose a significant health burden in Singapore. An estimated 600,000 adults are currently living with obesity2–4, a condition associated with more than 200 health complications5. Despite its prevalence and medical complexity, obesity remains heavily stigmatised—often misunderstood as merely the result of poor personal choices. Individuals living with obesity frequently face discrimination and mental health challenges which further isolate them. This misplaced blame, rather than targeting the disease itself, creates barriers to and slows the advancement of effective obesity treatment. Recognised by World Health Organization as a chronic disease6, obesity requires compassionate evidence-based care. The launch of Wegovy® (semaglutide 2.4mg) in Singapore provides a new treatment option for weight management available through private prescription.
Dr Abel Soh, Abel Soh Diabetes, Thyroid and Endocrine Clinic and Chairperson for Endocrine and Metabolic Society of Singapore (EMSS) stated, 'Obesity is not simply the result of lifestyle choices — it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones, and environment. In my clinical practice, I see firsthand how many individuals blame themselves when in fact, their biology is often working against them. It's time we shift the conversation from blame to support in the management of individuals with obesity'
Lifestyle factors in Singapore further contribute to the challenge. In Singapore's demanding work culture—where full-time employees work an average of 44.6 hours per week7, with time constraints and fatigue frequently cited as barriers to maintaining regular physical activity. These circumstances underscore the importance of comprehensive treatment strategies that facilitate the adoption of healthier lifestyles, including increased physical activity and a reduced-calorie diet, as integral components of long-term weight management.
Mr Vincent Siow, General Manager, Novo Nordisk Singapore, said 'With treatments like Wegovy® (semaglutide 2.4mg) now available in Singapore, we have an opportunity to provide healthcare professionals with more evidence-based options to support their patients in regaining control of their health and improving long-term outcomes.'
References: Wegovy Singapore Prescribing Information, February 2025 Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508. World Obesity. Retrieved from https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity World Obesity. Retrieved from https://data.worldobesity.org/country/singapore-192/ Scott I. Kahan, MD, MPH. Practical Strategies for Engaging Individuals With Obesity in Primary Care. Mayo Clin Proc. 2018;93(3):351-359 2. CDC, Cancers Associated with Overweight and Obesity Makeup 40 percent of Cancers Diagnosed in the United States. Available at https://www.cdc.gov/media/releases/2017/p1003-vs-cancer-obesity.html. World Health Organization. (2024). Obesity and overweight.WHO.https://www.who.int/news-room/factsheets/detail/obesity-and-overweight As accessed on 22nd May 2025. Leu J, Rebello SA, Sargent GM, Kelly M, Banwell C. Hard work, long hours, and Singaporean young adults' health. A qualitative study. Frontiers in Public Health. 2023; 11. https://doi.org/10.3389/fpubh.2023.1082581
Hashtag: #NovoNordisk #Wegovy
The issuer is solely responsible for the content of this announcement.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs around 77,400 people in 80 countries and markets its products in around 170 countries. In Singapore, Novo Nordisk has been present since 1997 and has approximately 100 employees.
For more information, visit novonordisk.sg.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
3 days ago
- Zawya
Novo Nordisk partners with Saudi Heart Association to improve cardiovascular health in Saudi Arabia
Riyadh, Saudi Arabia, - Novo Nordisk, a leading global healthcare company, is excited to announce a new Memorandum of Understanding with the Saudi Heart Association (SHA), aimed at improving cardiovascular care throughout Saudi Arabia. This strategic partnership will engage clinicians in a series of educational and research initiatives designed to provide optimal, multidisciplinary care for patients across the Kingdom. The collaboration seeks to enhance patient outcomes nationwide by equipping healthcare professionals with vital knowledge and resources. This effort aligns with the objectives of Saudi Vision 2030, which aims to address the clinical and economic challenges posed by cardiovascular disease. Cardiovascular diseases present a significant public health challenge in Saudi Arabia, with rising rates of related major risk factors, including obesity, diabetes, and inflammation. Besides traditional risk factors, systemic low-grade inflammation is nowadays recognized as a driving force of atherosclerotic disease progression and plaque destabilization. In 2016, approximately 201,300 Saudi nationals were affected by cardiovascular diseases, accounting for over 45% of fatalities in the country. This partnership is dedicated to tackling these pressing issues by fostering effective management strategies and enhancing clinical practices. Novo Nordisk and SHA are committed to establishing a comprehensive framework for early intervention, significantly improving the quality of care provided to patients. The partnership will leverage diverse communication channels to reach healthcare providers, delivering thorough education on the latest advancements in cardiovascular care. "At Novo Nordisk, we understand the critical importance of collaboration in advancing cardio care," said Melvin D'Souza, General Manager at Novo Nordisk Saudi Arabia. "Our partnership with the Saudi Heart Association marks a proactive step toward enhancing cardiovascular health practices and ultimately improving patient outcomes across the Kingdom." "We are thrilled about this collaboration with Novo Nordisk and its potential impact," stated Dr. Waleed AlHabeeb, President of the Saudi Heart Association. "By working together, we can empower healthcare providers with the essential knowledge and skills to effectively manage cardiovascular patients, contributing to a healthier future for our communities." About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. About Saudi Heart Association Saudi Heart Association (SHA) is a professional organization dedicated to advancing the field of cardiology in Saudi Arabia. Founded in 1987, it serves as a scientific reference for local bodies and works to disseminate knowledge and best practices in cardiovascular health. SHA is involved in various activities, including research, training, and public awareness campaigns, and hosts an annual Contacts for further information Media: Julie Andersen Public Affairs Specialist LJRT@ Islam Tawfik Sr. Medical Manager IZQT@ References Tash, Adel Abdulkader and Al-Bawardy, Rasha Fahad (2023) "Cardiovascular Disease in Saudi Arabia: facts and the way forward," Journal of the Saudi Heart Association: Vol. 35: Iss. 2, Article 6. Available at:
Arabian Post
4 days ago
- Arabian Post
Singapore Welcomes Wegovy® as a New Prescription Weight‑Loss Option
A once-weekly injection of Wegovy® has become available in Singapore, marking the latest step in managing obesity as a chronic disease. The product, from Novo Nordisk, is licensed for adults and those aged 12 and above who are obese or overweight with at least one weight‑related condition such as hypertension, type 2 diabetes or dyslipidemia. The drug works by mimicking the gut hormone GLP‑1, promoting a sense of fullness and reducing food intake when combined with healthier diet and exercise regimes. Its introduction follows approval by the Health Sciences Authority on 28 February 2025 for use among adolescents with obesity—a first in the region. Over 600,000 adult Singaporeans are classified as obese, a figure that underlines the public health urgency given the hundreds of comorbidities associated with obesity. The rollout of Wegovy® offers a medically guided therapy for a condition too often dismissed as a lifestyle issue. ADVERTISEMENT Clinical experts argue obesity stems from complex biological factors, ranging from genetics to hormonal imbalances. Dr Abel Soh, chair of the Endocrine and Metabolic Society of Singapore, says, 'Obesity is not simply the result of lifestyle choices—it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones and environment'. Approval comes amid global strain on semaglutide supplies. Local clinics previously stocked Ozempic and Rybelsus and faced intermittent shortages, with expectant Wegovy® shipments deferred until 2026 according to some medical guides. Private clinics were unable to reference branded drugs until local stock arrived, due to regulatory restrictions. Available through prescription in private settings, Wegovy® will be offered alongside diet and exercise interventions. The injectable is indicated for chronic use; ongoing physician oversight is advised. Regulatory approval includes a requirement to review treatment after 12 weeks in adolescents if BMI reduction falls below 5% on the full 2.4 mg dose. Globally, Wegovy® was first authorised in the US in June 2021, followed by EU approval in early 2022. Earlier, in Singapore, semaglutide received approval under Ozempic's label starting March 2023 for diabetic therapy. The drug's effectiveness has been supported by the STEP clinical programmes, showing average weight reductions of between 10–15% over periods of 68 to 104 weeks. Benefits extend beyond weight loss to metabolic health improvements, including lower blood pressure and decreased cholesterol. Local uptake may mirror global patterns, where appetite suppression and metabolic regulation paired with lifestyle changes have delivered sustainable weight loss without surgery. However, supply challenges persist: healthcare providers warn that stocks may remain tight, with some expect delays or patient referrals under the Ozempic brand. Novo Nordisk has also updated its savings programme for Wegovy®, making it more accessible to cash‑paying patients. The initiative aims to reduce financial barriers, although uptake and cost‑effectiveness will depend on real‑world pricing and insurance coverage.
Zawya
4 days ago
- Zawya
Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management
Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least one related health condition. The once-weekly injectable supports weight loss when used alongside a reduced-calorie diet and increased physical activity. The launch marks a step toward evidence-based, compassionate treatment of obesity as a chronic disease—not a personal failing. SINGAPORE - Media OutReach Newswire - 12 July 2025 - A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy ® (semaglutide 2.4mg) in Singapore. Wegovy® (semaglutide 2.4mg) is a once-weekly injectable treatment indicated for chronic weight management in adults and adolescents (aged 12 and above) living with obesity (BMI ≥30 kg/m²), or who are overweight (BMI ≥27 kg/m² to <30 kg/m²) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia 1. It is used alongside a reduced-calorie diet and increased physical activity, supporting Singapore's efforts to improve population health. The treatment works by addressing one of the underlying biological drivers of obesity. Wegovy® (semaglutide 2.4mg) is a GLP-1 receptor agonist with 94% similarity to the body's natural GLP-1 hormone. It activates receptors involved in appetite regulation, helping individuals feel full sooner and reduce food intake 1. This mechanism supports weight loss when combined with sustainable lifestyle changes. The availability of Wegovy® (semaglutide 2.4mg) comes as obesity continues to pose a significant health burden in Singapore. An estimated 600,000 adults are currently living with obesity 2 - 4, a condition associated with more than 200 health complications 5. Despite its prevalence and medical complexity, obesity remains heavily stigmatised—often misunderstood as merely the result of poor personal choices. Individuals living with obesity frequently face discrimination and mental health challenges which further isolate them. This misplaced blame, rather than targeting the disease itself, creates barriers to and slows the advancement of effective obesity treatment. Recognised by World Health Organization as a chronic disease 6, obesity requires compassionate evidence-based care. The launch of Wegovy® (semaglutide 2.4mg) in Singapore provides a new treatment option for weight management available through private prescription. Dr Abel Soh, Abel Soh Diabetes, Thyroid and Endocrine Clinic and Chairperson for Endocrine and Metabolic Society of Singapore (EMSS) stated, "Obesity is not simply the result of lifestyle choices — it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones, and environment. In my clinical practice, I see firsthand how many individuals blame themselves when in fact, their biology is often working against them. It's time we shift the conversation from blame to support in the management of individuals with obesity" Lifestyle factors in Singapore further contribute to the challenge. In Singapore's demanding work culture—where full-time employees work an average of 44.6 hours per week 7, with time constraints and fatigue frequently cited as barriers to maintaining regular physical activity. These circumstances underscore the importance of comprehensive treatment strategies that facilitate the adoption of healthier lifestyles, including increased physical activity and a reduced-calorie diet, as integral components of long-term weight management. Mr Vincent Siow, General Manager, Novo Nordisk Singapore, said "With treatments like Wegovy ® (semaglutide 2.4mg) now available in Singapore, we have an opportunity to provide healthcare professionals with more evidence-based options to support their patients in regaining control of their health and improving long-term outcomes." References: Wegovy Singapore Prescribing Information, February 2025 Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508. World Obesity. Retrieved from World Obesity. Retrieved from Scott I. Kahan, MD, MPH. Practical Strategies for Engaging Individuals With Obesity in Primary Care. Mayo Clin Proc. 2018;93(3):351-359 2. CDC, Cancers Associated with Overweight and Obesity Makeup 40 percent of Cancers Diagnosed in the United States. Available at World Health Organization. (2024). Obesity and overweight. As accessed on 22nd May 2025. Leu J, Rebello SA, Sargent GM, Kelly M, Banwell C. Hard work, long hours, and Singaporean young adults' health. A qualitative study. Frontiers in Public Health. 2023; 11. Hashtag: #NovoNordisk #Wegovy The issuer is solely responsible for the content of this announcement. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs around 77,400 people in 80 countries and markets its products in around 170 countries. In Singapore, Novo Nordisk has been present since 1997 and has approximately 100 employees. For more information, visit Novo Nordisk
